FMS: Functional Change With MMS

Sponsor
Zeltiq Aesthetics (Industry)
Overall Status
Unknown status
CT.gov ID
NCT04506502
Collaborator
(none)
45
1
1
20.9
2.2

Study Details

Study Description

Brief Summary

Evaluate the safety and efficacy of magnetic muscle stimulation (MMS) of abdominal muscle.

Condition or Disease Intervention/Treatment Phase
  • Device: The ZELTIQ System
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
45 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Functional Changes With Magnetic Muscle Stimulation of Abdominal Muscle
Actual Study Start Date :
Aug 3, 2020
Anticipated Primary Completion Date :
May 1, 2021
Anticipated Study Completion Date :
May 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Muscle Toning

The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.

Device: The ZELTIQ System
The MMS device will be used to perform the treatments.

Outcome Measures

Primary Outcome Measures

  1. Body Satisfaction Scale (BSS) [4-wk follow up visit]

    Change in subject perception of body shape using the Body Satisfaction Scale (BSS) at the 4-Week follow-up visit.

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Inclusion Criteria

  • Subject (healthy volunteer) has read and signed the study written informed consent form.

  • Male or female ≥ 22 years and ≤65 years of age.

  • Subject has not had weight change exceeding 5% of body weight in the preceding month.

  • Subject agrees to maintain body weight within 5% during the study by not making any changes in diet or exercise routine during the course of the study.

  • Subject has a BMI ≤ 30 as determined at screening.

  • Subject agrees to have photographs taken of the treatment area(s) during the scheduled time periods.

  • Subject agrees to refrain from any new abdominal muscle training exercises of the treatment area during the course of the study.

Exclusion Criteria

  • Subject has had a recent surgical procedure(s) in the area of intended treatment and muscle contractions may disrupt the healing process.

  • Subject needs to administer or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.

  • Subject has had an intrauterine contraceptive device inserted or removed within the past month.

  • Subject has a bleeding disorder or hemorrhagic condition

  • Subject is taking or has taken diet pills or supplements within the past month.

  • Subject has an active implanted electrical device such as a cardiac pacemaker, cochlear implant, intrathecal pump, hearing aids, defibrillator, or drug delivery system.

  • Subject has metal or electronic implants in or adjacent to the treatment area

  • Subject has an abdominal hernia.

  • Subject has pulmonary insufficiency.

  • Subject has a cardiac disorder.

  • Subject has a malignant tumor.

  • Subject has been diagnosed with a seizure disorder such as epilepsy.

  • Subject currently has a fever.

  • Subject is diagnosed with Grave's disease.

  • Subject has a growth plate in the treatment area

  • Subject is pregnant or intending to become pregnant during the study period (in the next 9 months).

  • Subject is lactating or has been lactating in the past 6 months.

  • Subject is unable or unwilling to comply with the study requirements.

  • Subject is currently enrolled in a clinical study of any unapproved investigational device, investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.

  • Any other condition or laboratory value that would, in the professional opinion of the Investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Innovation Research Center Pleasanton California United States 94588

Sponsors and Collaborators

  • Zeltiq Aesthetics

Investigators

  • Study Director: Kerrie Jiang, NP, Zeltiq Aesthetics

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zeltiq Aesthetics
ClinicalTrials.gov Identifier:
NCT04506502
Other Study ID Numbers:
  • ZA19-003
First Posted:
Aug 10, 2020
Last Update Posted:
Aug 10, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 10, 2020